Carisma Therapeutics, Inc.CARMNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+69.7%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
+69.7%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
14.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 858.29% |
| Q2 2025 | 38.10% |
| Q1 2025 | 47.72% |
| Q4 2024 | -35.84% |
| Q3 2024 | -12.63% |
| Q2 2024 | 40.18% |
| Q1 2024 | 13.10% |
| Q4 2023 | -0.47% |
| Q3 2023 | -6.58% |
| Q2 2023 | 8.74% |
| Q1 2023 | -49.93% |
| Q4 2022 | 8.53% |
| Q3 2022 | -20.23% |
| Q2 2022 | -37.19% |
| Q1 2022 | -332.72% |
| Q4 2021 | 142.57% |
| Q3 2021 | -12.66% |
| Q2 2021 | 30.94% |
| Q1 2021 | -46.62% |
| Q4 2020 | -192.23% |
| Q3 2020 | 60.98% |
| Q2 2020 | 36.01% |
| Q1 2020 | -41.26% |
| Q4 2019 | 11.50% |
| Q3 2019 | 6.72% |
| Q2 2019 | -36.43% |
| Q1 2019 | 5.20% |
| Q4 2018 | -13.46% |
| Q3 2018 | -40.29% |
| Q2 2018 | 1.48% |
| Q1 2018 | -2.24% |
| Q4 2017 | 2.99% |
| Q3 2017 | -1.94% |
| Q2 2017 | -10.47% |
| Q1 2017 | 19.92% |
| Q4 2016 | -124.95% |
| Q3 2016 | 459.42% |
| Q2 2016 | 11.41% |
| Q1 2016 | 43.83% |
| Q4 2015 | -4.99% |